Saved
cooleydd's Archive on May 07, 2008
10 Views
1 Member
Clipping
To perform a retrospective analysis to assess the utility of pretreatment serum prostatic acid phosphatase (PAP) as a predictor of cause-specific survival (CSS) in patients with higher risk prostate cancer treated with palladium-103 (103Pd) brachytherapy and supplemental external beam radiotherapy (EBRT).
Saved Without Comments By
cooleydd